Biocytogen Launches AI-Powered RenSuper™ Platform and Industry-First Fully Automated Antibody Discovery Infrastructure

Biocytogen today announced the launch of RenSuper Workstation, a next-generation AI-powered antibody discovery platform providing off-the-shelf access to a large-scale, experimentally validated library of fully human therapeutic antibody sequences, together with the RenSuper High-Throughput Antibody Manufacturing Automation Center, a fully automated infrastructure designed to accelerate antibody validation and production.

Built on Biocytogen’s proprietary RenMice^® platforms, RenSuper establishes a closed-loop antibody discovery engine combining in vivo immune repertoires, AI-driven candidate selection, automated experimental validation, and scalable manufacturing infrastructure. The platform supports the discovery and development of monoclonal antibodies, bispecifics, multispecifics, antibody-drug conjugates (ADCs), VHHs, and other advanced therapeutic modalities, significantly reducing the time and risk associated with antibody discovery.

RenSuper Workstation: AI-Powered One-Click Target-to-Lead Therapeutic Antibody Discovery

RenSuper Workstation introduces a new paradigm for one-click therapeutic antibody discovery, transforming antibody discovery from a project-based workflow into a searchable and programmable system. The platform enables rapid identification of high-quality therapeutic candidates with strong developability, functional relevance, and translational potential.

Proprietary Fully Human Antibody Library

The platform provides off-the-shelf access to fully human antibody sequences against more than 1,000 validated targets, complete with data packages to support more confident decision-making.

AI-Powered Candidate Selection

RenSuper’s AI models are trained on more than 100 million biologically validated antibody sequences, enabling efficient candidate identification against structurally and biologically challenging targets.

Using Biocytogen’s RenNano^® fully human HCAb platform as an example, the AI-powered screening workflow achieved an average positive hit rate of 46%, with peak hit rates reaching 98%. The workflow also enriched candidates with superior developability profiles and delivered an 82% success rate for high-purity (≥90%) Fc-format antibody expression.

Experimentally Validated Antibody Sequences

All AI-selected antibody sequences undergo experimental validation, including binding, affinity, and specificity characterization, ensuring reproducibility, reliability, and downstream development readiness.

One-Click Search & Design

The platform enables one-click filtering and comparison of antibody candidates by target, epitope, and physicochemical properties. An integrated antibody design platform further supports rapid sequence assembly and flexible format design across multiple therapeutic modalities.

Learn more about RenSuper Workstation: https://www.rensuperbio.com/

RenSuper High-Throughput Automation Center

Beyond intelligent discovery, RenSuper integrates industrial-scale automation to establish a scalable, closed-loop antibody development engine.

The newly launched automation center enables high-throughput experimental validation of AI-selected antibody candidates with minimal manual intervention, significantly accelerating the transition from molecular design to functional evaluation.

The fully automated platform spans the entire protein production workflow, including bacterial inoculation, plasmid extraction, transfection, fed-batch cultivation, and purification.

The system consistently delivers antibody yields averaging 50-100 mg, with throughput of up to 800 samples per day and over 5,000 samples per week, transforming antibody validation from a labor-intensive process into a scalable industrial workflow.

“We believe the future of antibody discovery will be driven by speed, scale, and data-driven intelligence,” said Dr. Yuelei Shen, Founder and CEO of Biocytogen. “With RenSuper, we are building an intelligence-native system that makes antibody discovery more intelligent, scalable, and efficient. Our goal is to reduce the time and complexity of early-stage discovery, accelerate the development of innovative therapeutics, and bring new medicines to patients faster.”

Together, RenSuper Workstation and the RenSuper High-Throughput Automation Center establish a next-generation target-to-lead ecosystem powered by biologically validated immune repertoires, artificial intelligence, and industrial-scale automation.

This milestone further reinforces Biocytogen’s vision of becoming the “Global Headstream of New Drugs” by transforming therapeutic antibody discovery into a more intelligent, scalable, and programmable process for biologics innovation worldwide.

About Biocytogen

Biocytogen (SSE: 688796; HKEX: 02315) is a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies. Founded on gene editing technology, Biocytogen has established a dual-engine platform combining a fully human antibody library with an extensive target-humanized mouse model portfolio, enabling a systematic approach to accelerating global drug discovery and development.

Biocytogen has independently developed its proprietary RenMice^® (RenMab^®/RenLite^®/RenNano^®/RenTCR™/RenTCR mimic™) platforms for fully human monoclonal/bispecific/multispecific antibody discovery, bispecific antibody-drug conjugate discovery, hu-VHH discovery, and TCR mimic antibody discovery, and has established a sub-brand, RenSuper™ Biologics, to explore global partnerships for an off-the-shelf library of >1,000,000 fully human antibody sequences against over 1000 targets for worldwide collaboration. As of December 31, 2025, more than 350 agreements for therapeutic antibodies and clinical assets—spanning co-development, out-licensing, and transfers—have been established globally, including landmark partnerships with leading multinational pharmaceutical companies (MNCs). Biocytogen pioneered the generation of drug target knock-in humanized models for preclinical research, and currently provides a few thousand off-the-shelf animal and cell models under the company's sub-brand, BioMice™, along with preclinical pharmacology and gene-editing services for clients worldwide. Headquartered in Beijing, Biocytogen has branches in China (Haimen, Jiangsu, Shanghai), the USA (Boston, San Francisco, San Diego), and Germany (Heidelberg). For more information, please visit https://biocytogen.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20260526676192/en/